Core Viewpoint - Tong Ren Tang Technologies (600085) announced the resignation of non-executive director Mr. Chen Fei due to job changes, effective upon the appointment of a new non-executive director at the upcoming shareholders' meeting [1] Group 1 - Mr. Chen Fei's resignation will take effect after the election of a new non-executive director at the shareholders' meeting [1] - The board has proposed the appointment of Ms. Du Xin as the new non-executive director, pending approval at the shareholders' meeting [1] - The appointment of Ms. Du Xin must comply with the company's articles of association and requires shareholder approval to be finalized [1]

Core Viewpoint - Tong Ren Tang Technologies (01666.HK) announced the resignation of non-executive director Chen Fei due to job changes, effective upon the election of a new non-executive director at the upcoming shareholders' meeting [1] Group 1 - Chen Fei's resignation will take effect after the shareholders' meeting where a new non-executive director is elected [1] - The board has proposed the appointment of Du Xin as a non-executive director, pending approval at the shareholders' meeting [1]

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不會就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承 擔任何責任。 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名下之北京同仁堂科技發展股份有限公司股份全部售出或轉讓，應立即將本通函及隨附之代理人委 任表格送交買主或承讓人或經手買賣或轉讓之銀行、持牌證券交易商或其他代理商，以便轉交買主或承讓人。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 建議續訂持續關連交易； 建議委任新董事； 及 股東特別大會通告 獨立董事委員會及獨立股東之獨立財務顧問 董事會函件載於本通函第5頁至第29頁。獨立董事委員會函件載於本通函第30頁至第31頁，當中載有其致獨立股 東之推薦意見。獨立財務顧問函件載於本通函第32頁至第55頁，當中載有其致獨立董事委員會及獨立股東之意見。 本公司謹訂於二零二五年十二月三十日（星期二）上午九時三十分假 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1666） 公告 董事變更 董事會謹此宣佈，於二零二五年十一月二十八日，非執行董事陳飛先生由於工 作變動申請辭任非執行董事。陳飛先生之辭任將自本公司適時召開的股東大會 上選出新任非執行董事起生效。 於二零二五年十一月二十八日，董事會建議委任杜欣女士為非執行董事。根據 本公司公司章程，該委任須待股東於股東大會上批准後方可落實。 載有有關上述議案詳細資料的本公司通函將適時寄發予股東。 1 董事會於二零二五年十一月二十八日進一步宣佈，建議委任杜欣女士（「杜女士」）為 非執行董事。根據本公司公司章程，該委任須待股東於股東大會上批准後方可落實。 杜女士之履歷 杜欣女士，48歲，中級經濟師，杜女士於一九九九年七月獲得北京化工大學工學學士學位， 並於二零零四年十二月獲得中央財經大學經濟學碩士學位。曾任中國北京同仁堂（集團） 有限責任公司（「集團公司」）對外經 ...

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. has successfully integrated traditional Chinese medicine with modern cultural creativity, exemplified by its award-winning product "Four Seasons Harmony" at the 2025 "Beijing Gift" Global Cultural and Creative Competition [3][12]. Group 1: Product Development and Innovation - The "Four Seasons Harmony" product line won the "Scene Application" award at the 2025 "Beijing Gift" Global Cultural and Creative Competition, which received 4,410 submissions since its launch in July [3]. - The product development is rooted in traditional Chinese medicine, utilizing ancient texts and seasonal health principles to create fragrances that align with the body's needs throughout the year [5][7]. - The company has developed over 100 cultural and creative fragrance products, including "Anping Fragrance," "Ankang Fragrance," and "Four Seasons Harmony," forming a diverse product matrix that includes incense, herbal fragrances, and essential oils [7][12]. Group 2: Market Strategy and Distribution - The fragrance products are available in Tongrentang's nationwide chain pharmacies and have established partnerships with major bookstores in Beijing, Xi'an, Shanghai, and Fujian to enhance offline sales [8]. - The company actively promotes traditional Chinese medicine culture through experiential activities in schools and public spaces, aiming to educate participants about the heritage of traditional medicine [10]. Group 3: Future Outlook - The company plans to continue focusing on the integration of global creativity with Beijing's cultural heritage, aiming to launch more high-quality products that reflect the essence of Tongrentang's traditional medicine culture and meet consumer demands for holistic health [12].

Core Insights - Beijing Tongrentang's "Bencao Zhi Yue" fragrance products are rooted in traditional Chinese medicine and aim to integrate medicinal scents into daily life [3][5] - The company has developed over 100 products across five major series, including incense, bracelets, ornaments, sachets, and essential oils, leveraging traditional formulas [3][5] - The entry into the "Yuxun Jingxi" cultural space is a strategic move to enhance brand influence and promote traditional Chinese medicine culture [5][9] Product Development - The fragrance products are based on classic Tongrentang formulas such as Niuhuang Qingxin Wan and Suhe Xiang Wan, embodying the concept of "medicinal scent" [3] - The company has rapidly expanded its cultural and creative product line, showcasing its offerings at various industry exhibitions and cultural markets [3][5] Market Positioning - The "Yuxun" brand, established by Beijing Gongmei Group in 2023, targets young consumers and aims to transform traditional craftsmanship into modern consumer products [7] - "Yuxun Jingxi" is designed as a multi-functional cultural space that promotes immersive cultural experiences, aligning with the trend of integrating traditional heritage into contemporary consumption [9] Strategic Goals - The company aims to deepen the integration of its medicinal fragrance products into consumer lifestyles and enhance the cultural consumption landscape [3][9] - Future plans include launching more products that combine Tongrentang's unique characteristics with market appeal, focusing on consumer needs [9]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 2. 股份分類 ...

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [2][6] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [4] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility [6] Company Developments - The new production line will increase the company's total liquid preparation production capacity to 240 million bottles annually, with a maximum daily capacity of 800,000 bottles [2] - Key equipment upgrades include a new water bath sterilizer with a 42.8% increase in capacity and an AI-driven automatic light inspection machine for optimized detection parameters [6] - The company is advancing its "smart production line" initiative, focusing on data integration across the entire supply chain from planting to production and consumption [6] Market Trends - The main categories driving the market include medications for respiratory diseases, tonics for energy and blood, and digestive system diseases [4] - Tongrentang Technology's oral liquid products, such as Shenmai Drink and Children's Cough Syrup, are gaining traction due to their quick efficacy, precise dosing, and ease of use, aligning with modern consumer demands [4]

Core Insights - Tongrentang Technology has successfully completed the trial operation of its export product workshop, marking a significant step towards the official production of its "export product production and R&D base" [1][3] Group 1: Production Capabilities - The company produces nearly 200 varieties of traditional Chinese medicine, covering over 20 dosage forms, which supports its overseas business growth [3] - The newly established export product production and R&D base has a construction area of over 1,400 square meters and is equipped with advanced pharmaceutical equipment and testing instruments [3][6] - The base is designed to meet the production and testing needs of 66 product specifications, including water honey pills, granules, and tablets, ensuring a robust supply for overseas markets [3][6] Group 2: Market Adaptation - The establishment of the export base allows for production tailored to the regulatory requirements of target markets, creating a more specialized supply system [3] - The base focuses on producing dosage forms that are more acceptable to overseas consumers, addressing cultural differences in consumption habits [3] Group 3: Quality Assurance - The trial operation tested the stability, production efficiency, and product quality, with results showing uniform granule size and excellent tablet formation [5][6] - The successful trial operation validates the "practical capabilities" of the export product workshop, enhancing the confidence in Tongrentang's international expansion [6] Group 4: Strategic Vision - The establishment of a dedicated export base enables the company to quickly respond to international market changes and systematically address the barriers faced by traditional Chinese medicine in global markets [6] - The company aims to transition from "able to export" to "good export" and ultimately to "brand export," fostering long-term trust and brand premium in international markets [6] - Future plans include optimizing production processes and advancing supporting work to achieve full production at the base, enhancing the international competitiveness of traditional Chinese medicine [6]

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [1] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [3] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility in response to market demands [6] Group 1 - The new production line will increase the company's total capacity to four liquid preparation lines, with a maximum daily output of 800,000 bottles and an annual designed capacity exceeding 240 million bottles [1] - Key product categories driving market growth include medications for respiratory diseases, tonics, and digestive system diseases, with Tongrentang's oral liquid products benefiting from their quick efficacy and ease of use [3] - The introduction of advanced equipment, such as a new water bath sterilizer with a 42.8% increase in capacity and AI-enhanced automatic inspection machines, will further optimize production processes [6] Group 2 - The company is advancing its "smart production line" initiative, integrating data across the entire supply chain from cultivation to production, distribution, and consumption [6] - The deployment of a visual "cockpit" system in the workshop allows for real-time monitoring of production progress and key milestones, supporting resource utilization and cost control [6] - By embedding technological innovation into its operations, Tongrentang Technology aims to strengthen its competitive advantage in the modern traditional Chinese medicine sector, enhancing product innovation and operational efficiency [6]